Pipeline

TG-1801 (CD47/CD19 Bispecific Antibody)

TG-1801 is the first therapy to target both CD19, a B-cell specific market widely express across B-cell malignancies, and CD47, the "dont eat me" signal used by both healthy and tumor cells to evade macrophage mediated phagocytosis. CD47 is expressed ubiquitously on normal cells, including red blood cells and platelets. By co-targeting both CD47 and CD19, TG-1801 has the potential to overcome the limitations of existing CD47 targeted therapies by avoiding the side effects caused by indiscriminate blockage of CD47 on helathy cells. Moreover, the co-targeting of CD19 is not only expected to enhance safety bu by retaining IgG1 Fc functionality, this agent is designed to provide a seconday mechanism of anti-tumor activity through the induction of antibody dependent cellular cytotoxicity (ADCC). 

TG-1801 is now the first anti-CD47/CD19 bispecific antibody to initiate a Phase 1 clinical trial.